Comparable stake leader
YA II PN, Ltd.
SEC ownership of Transcode Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001829635.
Disclosed value leader
Anna Moore
Comparable rows
13/20
Latest evidence
17 Jul 2026
- Public ticker
- RNAZ on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
YA II PN, Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
13 of 20
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
YA II PN, Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
17 Jul 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001829635
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Transcode Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
YA II PN, Ltd.
Disclosed value leader
Anna Moore
Comparable rows
13/20
Latest evidence
17 Jul 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
7 rows are not safely comparable across share classes.
13D/G row: YA II PN, Ltd.
Showing 1-8 of 20 holder rows.
Quick read
YA II PN, Ltd. leads the comparable SEC ownership view at 9.9%.
13 of 20 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens YA II PN, Ltd.'s linked filing trail.
Comparable ownership
Top 5
YA II PN, Ltd.
9.9%
CK Life Sciences Intl (Holdings) Inc
8.8%
Thomas Joseph Tracy
5%
SABBY MANAGEMENT, LLC
4.9%
Anson Funds Management LP
0.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 20 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| YA II PN, Ltd. |
13D/G
|
9.9%
|
$35,620
101,772 shares
|
$0 | 15 Apr 2026 |
| CK Life Sciences Intl (Holdings) Inc |
13D/G
CK Life Sciences Int'l., (Holdings) Inc.
|
8.8%
|
$413,926
83,285 shares
|
$0 | 17 Jul 2026 |
| Thomas Joseph Tracy |
13D/G
|
5%
|
$13,300
35,000 shares
|
$0 | 07 Mar 2025 |
| SABBY MANAGEMENT, LLC |
13D/G
|
4.9%
|
$433,482
41,601 shares
|
$0 | 31 Dec 2025 |
| Anson Funds Management LP |
13D/G
|
0.1%
|
$9,494
27,125 shares
|
-$30,224 | 30 Jun 2025 |
| GOLDMAN SACHS GROUP INC |
13D/G
THE GOLDMAN SACHS GROUP, INC.
|
0.01%
|
$882
82 shares
|
-$526,307 | 30 Sep 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.3%
|
$109,690
12,740 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
0.88%
|
$71,420
8,295 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 17 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to Transcode Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Anna Moore
Net 12M change
$0
Latest report
19 Dec 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anna Moore | 10%+ Owner | $791,920 | Mixed | 08 Jul 2021 | ||
| Robert Michael Dudley | Chief Executive Officer, Director | $91,934 | Filing P/S | 28 Sep 2023 | ||
| Thomas A. Fitzgerald | Interim CEO, CFO, Director | $28,722 | Filing P/S | 14 Jun 2024 | ||
| Philippe Calais | Director | Mixed | 14 Jun 2024 | |||
| Jack E. Stover | Director | Mixed | 19 Dec 2025 | |||
| Erik Manting | Director | Mixed | 14 Jun 2024 | |||
| Elizabeth Czerepak | Director | Mixed | 06 Oct 2025 | |||
| Magda Marquet | Director | Mixed | 14 Jun 2024 | |||
| Zdravka Medarova | Chief Technology Officer, 10%+ Owner | Mixed | 12 Dec 2022 |
Recent insider transactions for Transcode Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.